Cargando…
Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients
Brepocitinib is a tyrosine kinase 2 and Janus kinase 1 inhibitor in development for treatment of inflammatory autoimmune diseases. This analysis aimed to add to the pharmacokinetic knowledge of the medication, through development of a population pharmacokinetic model and identification of factors th...
Autores principales: | Hughes, Jim H., Qiu, Ruolun, Banfield, Christopher, Dowty, Martin E., Nicholas, Timothy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087980/ https://www.ncbi.nlm.nih.gov/pubmed/36045513 http://dx.doi.org/10.1002/cpdd.1163 |
Ejemplares similares
-
Does brepocitinib benefit patients with psoriatic arthritis?
Publicado: (2023) -
Pharmacokinetics of Oral Taurine in Healthy Volunteers
por: Ghandforoush-Sattari, Mohammadreza, et al.
Publicado: (2010) -
Pharmacokinetics of oral and intravenous melatonin in healthy volunteers
por: Andersen, Lars P. H., et al.
Publicado: (2016) -
Population Pharmacokinetic Model Characterizing 24-Hour Variation in the Pharmacokinetics of Oral and Intravenous Midazolam in Healthy Volunteers
por: van Rongen, A, et al.
Publicado: (2015) -
Population pharmacokinetics of olprinone in healthy male volunteers
por: Kunisawa, Takayuki, et al.
Publicado: (2014)